Welcome to our dedicated page for Orchestra BioMed Holdings SEC filings (Ticker: OBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an emerging growth company, Orchestra BioMed uses current reports on Form 8-K and other filings to describe material agreements, financings, collaborations and governance matters related to its biomedical innovation business.
In these filings, investors can find detailed information about the company’s strategic and financial arrangements that support its flagship programs, Atrioventricular Interval Modulation (AVIM) Therapy and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB). Recent Form 8-K reports describe revenue participation agreements with Ligand Pharmaceuticals tied to future revenues from AVIM Therapy and Virtue SAB, a secured subordinated convertible loan agreement with Medtronic that can convert into a revenue share, and a termination and right of first refusal agreement with Terumo related to Virtue SAB for coronary artery disease.
Filings also cover underwritten public offerings of common stock and pre-funded warrants, private placements with institutional partners, preferred stock issuances, and stock purchase agreements that provide capital for pivotal clinical trials such as the BACKBEAT global study and the Virtue Trial. Additional disclosures include investor presentations furnished under Regulation FD, conference call transcripts, and annual meeting voting results.
On Stock Titan, these OBIO filings are complemented by AI-powered summaries that highlight key terms, counterparties and financial implications, helping readers quickly understand complex documents such as Form 8-Ks, registration statements and related exhibits. Users can review how Orchestra BioMed structures revenue interests, rights of first refusal, convertible instruments and collaboration amendments, and can monitor ongoing reporting about its status as an emerging growth company and its relationships with partners like Medtronic, Terumo and Ligand.
On 24 June 2025 Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) filed a Form 8-K (Item 5.07) disclosing the final voting results of its 2025 Annual Meeting of Stockholders. Of the 38,312,512 shares entitled to vote, 28,177,159 shares (73.6%) were present in person or by proxy, establishing a quorum.
Proposal 1 – Election of Class II Directors (terms expiring 2028)
- Chris Cleary: 24,555,860 for / 64,650 withheld / 3,556,649 broker non-votes
- Pamela Connealy: 23,674,360 for / 946,150 withheld / 3,556,649 broker non-votes
- David Pacitti: 24,227,123 for / 393,387 withheld / 3,556,649 broker non-votes
All three nominees were elected by comfortable majorities.
Proposal 2 – Ratification of Independent Auditor
- Ernst & Young LLP re-appointed for the fiscal year ending 31-Dec-2025 with 28,140,709 for, 34,087 against and 2,363 abstentions (no broker non-votes).
No other matters were submitted and the filing provides no financial metrics, guidance or strategic updates. The disclosure is routine, focused solely on corporate governance housekeeping and does not indicate any immediate operational or financial impact.
Form 4 overview: Orchestra BioMed Holdings, Inc. (ticker OBIO) reported an insider transaction by Principal Accounting Officer Joshua Aiello on 06/18/2025.
Key details: 393 shares of "Common Stock, $0.0001 par value" were withheld (Transaction Code F) at a price of $2.99 per share to cover tax obligations triggered by the vesting of restricted stock units. No shares were sold on the open market.
Post-transaction ownership: Mr. Aiello now directly owns 4,329 OBIO shares. No derivative securities were reported, and no 10b5-1 trading plan box was marked.
Investor take-away: Code F transactions are administrative and typically have negligible market impact because they do not reflect discretionary buying or selling. The filing neither alters the company’s fundamentals nor signals a shift in insider sentiment.